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Background: Accurate tumor bed delineation after breast-conserving surgery is important. However, consistency
among observers on standard postoperative radiotherapy planning CT is low and volumes can be large due to
seroma formation. A preoperative delineation of the tumor might be more consistent. Therefore, the purpose of this
study was to determine the consistency of preoperative target volume delineation on CT and MRI for
breast-conserving radiotherapy.
Methods: Tumors were delineated on preoperative contrast-enhanced (CE) CT and newly developed 3D CE-MR
images, by four breast radiation oncologists. Clinical target volumes (CTVs) were created by addition of a 1.5 cm
margin around the tumor, excluding skin and chest wall. Consistency in target volume delineation was expressed
by the interobserver variability. Therefore, the conformity index (CI), center of mass distance (dCOM) and volumes
were calculated. Tumor characteristics on CT and MRI were scored by an experienced breast radiologist.
Results: Preoperative tumor delineation resulted in a high interobserver agreement with a high median CI for the
CTV, for both CT (0.80) and MRI (0.84). The tumor was missed on CT in 2/14 patients (14%). Leaving these 2 patients
out of the analysis, CI was higher on MRI compared to CT for the GTV (p < 0.001) while not for the CTV (CT (0.82) versus
MRI (0.84), p = 0.123). The dCOM did not differ between CT and MRI. The median CTV was 48 cm3 (range 28–137 cm3)
on CT and 59 cm3 (range 30–153 cm3) on MRI (p < 0.001). Tumor shapes and margins were rated as more irregular and
spiculated on CE-MRI.
Conclusions: This study showed that preoperative target volume delineation resulted in small target volumes with a
high consistency among observers. MRI appeared to be necessary for tumor detection and the visualization of
irregularities and spiculations. Regarding the tumor delineation itself, no clinically relevant differences in interobserver
variability were observed. These results will be used to study the potential for future MRI-guided and neoadjuvant
radiotherapy.
Trial registration: International Clinical Trials Registry Platform NTR3198.
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The standard treatment of early-stage breast cancer is
lumpectomy, or wide local excision, followed by whole
breast irradiation with an additional boost dose to the
tumor bed (TB) in patients with a higher risk of local re-
currence [1,2]. Since most local recurrences occur in or* Correspondence: M.denHartogh-3@umcutrecht.nl
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article, unless otherwise stated.nearby the TB, several accelerated partial breast irradiation
(APBI) studies are ongoing in early-stage breast cancer pa-
tients. APBI targets the breast tissue immediately sur-
rounding the TB. The advantages of APBI are a shorter
overall treatment time and a potential dose reduction in
the normal tissues (i.e. breast, heart and lung) compared
to whole breast irradiation [3]. Accurate TB delineation on
the radiotherapy planning CT scan after lumpectomy is
important for both TB boost irradiation and APBI. How-
ever, in radiotherapy practice, there is no gold standard toentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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after lumpectomy. As an alternative, consensus among ob-
servers is often used to assess the precision of our target
volume delineation. The degree of consensus is generally
called the interobserver variability (IOV), and quantified
by a conformity index (CI) which is the volume of agree-
ment among observers divided by the total encompassing
volume. The current CT guided delineation after lumpec-
tomy is prone to a high IOV. Several studies showed a low
CI and a large distance between the centers of mass
(dCOM) among observers [4-13].
Besides the high IOV in the current postoperative radio-
therapy setting, there is also the concern of large postopera-
tive treatment volumes due to seroma and hematoma
formation. Irradiation of these disproportionally large target
volumes can lead to extended subcutaneous fibrosis, poor
cosmetic results and even missing the target [14-17]. Fur-
thermore, these large volumes can cause low-risk patients
aiming for APBI to be ineligible for this treatment due to
the inability to meet the dose-volume constraints [18,19].
The poor consistency in target volume definition and
large volumes after lumpectomy might be avoided by ir-
radiating the tumor preoperatively. Since the tumor is
still in situ without any seroma formation, this would
probably lead to a high delineation precision and small
treatment volumes. Several groups are studying the po-
tential for neoadjuvant irradiation in early stage breast
cancer patients [18,20,21]. In these studies, IOV and
normal tissue dose were reduced, which shows that neo-
adjuvant irradiation could result in more precise target
volume definition and localization and smaller volumes
[20-22]. Furthermore, Bondiau et al. reported the feasi-
bility of a neoadjuvant stereotactic body irradiation in
combination with neoadjuvant chemotherapy in locally
advanced breast cancer patients [23].
Alternatively, preoperative imaging in radiotherapy
supine position might also have potential value to im-
prove the standard post-lumpectomy TB delineation,
since it provides additional information about the ori-
ginal tumor location [11].
To correctly delineate the tumor, imaging quality is of
great importance. Since it is unknown what the optimal
imaging modality for preoperative target volume delinea-
tion is, delineation was studied on both contrast-enhanced
(CE) CT and MRI. In daily clinical practice, CT is the
standard imaging modality for target volume delineation in
breast cancer patients. However, MRI has a superior soft
tissue contrast which can be explored with different se-
quences to show endogenous contrast or the distribution of
an administered contrast agent. This enables differentiation
between the tumor and benign lesions like post-biopsy
hematomas or cysts. Furthermore, MRI has a high sen-
sitivity for detection of invasive breast cancer and a
good correlation with histopathology findings [24,25].However, standard diagnostic MRI is performed in prone
position, while patients in most departments are irradiated
in supine position. Acquiring images in supine radiother-
apy position is generally limited by narrow bore sizes of
standard MRI scanners. Therefore a new MRI protocol
was designed in a wide bore MRI scanner.
The purpose of this study was to quantify the
consistency of preoperative target volume delineation
for breast-conserving radiotherapy. To identify the best
imaging modality for preoperative target volume delin-
eation, preoperative delineation was performed on both




The study was approved by our institutional review board
and registered in the International Clinical Trials Registry
Platform (NTR3198). Fourteen early-staged breast cancer
patients, scheduled for lumpectomy at the University
Medical Center Utrecht or St. Antonius hospital, were
included in this study. All patients gave written informed
consent. Patients eligible for inclusion had a clinical T1-T2,
N0 staged adenocarcinoma of the breast and were sched-
uled for lumpectomy and sentinel node procedure. Patients
with lobular carcinoma, a history of ipsilateral breast sur-
gery, contra-indications for 1.5 Tesla MRI, iodine allergy,
and patients who received neoadjuvant treatment were not
eligible. In case of additional suspected findings on study
MRI or CT imaging, patients were referred to their phys-
ician for additional diagnostic work-up.
Patient positioning and image acquisition
Patients underwent both CT and MRI in radiotherapy su-
pine position prior to surgery. On CT, they were positioned
with arms in abduction and hands above the head at 10° in-
clination and with the use of a knee support (C-Qual,
CIVCO medical solutions, Reeuwijk, The Netherlands). If
palpable, the tumor was marked on the skin with a CT/
MRI compatible wire. CE-CT images were obtained at
3 mm slice thickness and a minimal in-plane resolution
of 1 × 1 mm2 (Brilliance, Philips Medical Systems, Best,
The Netherlands), with a delay time of 120 s after intra-
venous contrast agent injection (Ultravist, 80 ml, 3 ml/s)
[11]. Delay time was shortened to 80s after the 6th patient
according to Kuroki-Suzuki et al. in attempt to improve
tumor enhancement [26].
For MRI, patients were positioned on an MRI compatible
10° wedge board (Thorawedge, CIVCO medical solutions,
Reeuwijk, The Netherlands). To acquire MR images, an an-
terior receive coil was used. To prevent breast deformation
by the anterior receive coil, a polymethyl methacrylate
(PMMA) support was designed, which is adjustable to pa-
tient habitus and breast size. MRI patient setup is shown in
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to acquire images in this position. Therefore, we used a
wide bore (70 cm) MRI scanner (Ingenia 1.5 T, Philips
Medical Systems, Best, The Netherlands). The following 3D
high resolution images were acquired: T1 weighted (T1w)
fast field echo (FFE) ± fat suppression (Dixon), T2 weighted
(T2w) turbo spin echo (TSE) + fat suppression, and a dy-
namic series of contrast-enhanced T1w images ± fat sup-
pression after contrast agent administration. For T1w
Dixon FFE MRI, acquired 3D resolution was 0.99 × 1.05 ×
2.19 mm3 reconstructed to 0.95 × 0.95 × 1.1 mm3 using
overcontiguous slices and for T2w TSE MRI, the voxels
measured 0.78 × 0.78 × 1.2 mm3 acquired with a resolution
of 1.25 × 1.32 × 2.41 mm3. In the dynamic T1w series, the
first 3D image was acquired before and 6 images after intra-
venous contrast injection (Gadobutrol (Gadovist, Bayer),
0.1 mmol/kg, 1 ml/s), at 60s intervals with an acquired
resolution of 1.20 × 1.21 × 2.41 mm3 reconstructed to
1.16 × 1.16 × 1.2 mm3 using overcontiguous slices. The total
acquisition time of this protocol was 21 minutes. Small dis-
placements between sequences during image acquisition
caused by patient motion were corrected for by using a
rigid mutual information registration on a box around the
tumor. No breast deformation by the anterior receive coil
was observed.
To quantify differences in tumor visualization on CT and
MRI, the shape (1–round, 2–oval, 3–lobular, 4–irregular)
and margin (1–smooth, 2–irregular, or 3–spiculated) of the
tumor were rated by an experienced breast radiologist [27].
Target volume delineation
Four experienced breast radiation oncologists independ-
ently delineated the GTV on both CT and MRI data,Figure 1 MRI patient setup in radiotherapy supine position.with at least a 4-week interval between delineation sessions,
using an in-house developed software tool (Volumetool)
[28]. Written delineation instructions were formulated in a
consensus meeting with all observers, supervised by an
experienced breast radiologist. MRI delineations were per-
formed on preoperative 3D CE T1w images with an indi-
vidually prescribed fixed window and level as determined by
an experienced breast radiologist. Observers were allowed
to consult other sequences, which were registered to the
CE-MRI series to differentiate between structures, i.e. tumor
(gadolinium uptake causes a high signal on CE T1w im-
ages), post-biopsy hematoma (blood causes a high signal on
both CE and non-CE T1w images), and cysts (fluid causes
a high signal on T2w images). Clinical target volumes
(CTVs) were created by adding a 1.5 cm margin around the
GTV, restricted by the chest wall and a 5 mm margin be-
neath the skin surface. Delineation of a preoperative GTV
different from the tumor location as confirmed during
histopathological examination of the lumpectomy specimen
(gold standard) was considered as ‘misdelineation’.Data analysis
The conformity index (CI) and distance between
the centers of mass (dCOM) for both the GTV and
CTV contours as delineated by the 4 observers were
calculated for all possible observer pairs. The CI per
observer pair was calculated by using the following for-
mula: CI ¼ volume of agreementtotal encompassing volume . Consequently, CI = 1
implies a perfect agreement among observers, while
CI = 0 means there is no overlap. For dCOM, a value of
0 means that two delineations are centered at the same
position.
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describe the data since not all variables were normally dis-
tributed. A Wilcoxon signed-rank test was performed to
compare paired variables using IBM SPSS Statistics 20
(Chicago, IL, USA) with a significance level of α = 0.05.
Results
Patients
Patient and tumor characteristics are shown in Table 1.
Median age was 61 years (range 48–70). Median clinical
tumor diameter (as measured on diagnostic ultrasound/
MRI) was 15 mm (range 7–30 mm), and median micro-
scopic tumor diameter (as measured by histopathological
examination) was 12 mm (range 6–29 mm). On CE-MRI,
tumor margins were scored more spiculated compared to
CE-CT (Table 1, Figure 2). Tumor shape was mainly scored
as an irregular mass on CE-MRI and as a lobular mass on
CE-CT.Interobserver variability and volumes
In Figure 3a and 3b, GTV delineations of the 4 ob-
servers are shown on both preoperative CE-CT and CE-
MRI in one patient. To illustrate the comparison with











Clinical tumor diameter (mm) 7-30
Median 15
Microscopic tumor diameter (mm) 6-29
Median 12
Tumor visualization score on CT (median)
Margin 2
Shape 3




Margin: 1 – smooth, 2 – irregular, or 3 – spiculated.
Shape: 1 – round, 2 – oval, 3 – lobular, 4 – irregular.postoperative delineations of this patient are shown in
Figure 3c as a clinical example.
Preoperative tumor delineation resulted in a high median
CI of the CTV, for both CT (0.80) and MRI (0.84)). How-
ever, the tumor was missed on CT in 2/14 patients (14%).
This resulted in wide ranges in CI on CT (range 0.00-0.93
for the CTV) compared to MRI (range 0.47-0.93). The first
patient in which misdelineation occurred was a patient
with multiple macrocalcifications in the breast, as seen on
mammography. On CE-MRI all 4 observers contoured the
tumor. On CE-CT a benign lesion was contoured by 3 ob-
servers, resulting in a CI ranging from 0.00 to 0.52. The
second patient had a tumor centrally located in the breast.
On CE-MRI all observers contoured the tumor, while on
CE-CT one observer contoured dense fibroglandular tis-
sue resulting in a range in CI of 0.00-0.59. Outcomes of
the analysis including misdelineations are provided as
Additional file 1.
To only focus on differences in contouring the actual
tumor, and not on tumor detection, the 2 misdelineations
were excluded from further IOV and volume analysis. Re-
sults of this analysis are shown in Table 2. The CI for the
GTV was significantly higher on MRI (p < 0.001) com-
pared to CT. No difference in CI for the CTV was found
(p = 0.123). Delineated volumes were significantly larger
on MRI for both the GTV and CTV (both p < 0.001).
There was no difference in dCOM between CT and MRI
for both the GTV and CTV.Discussion
To our knowledge, this is the first study in which the feasi-
bility of 3D CE-MRI of patients in radiotherapy supine
position using a wide bore MRI scanner has been demon-
strated. Different sequences of high resolution 3D CE and
non-CE images were acquired with isotropic voxel sizes ≤
1.2 mm.
In the present study, target volume delineation before
lumpectomy resulted in a high agreement and small
treatment volumes among observers compared to stand-
ard postoperative TB delineation as reported in literature
(Table 3).
Since the optimal imaging modality for preoperative tar-
get volume delineation was unknown, delineation was
studied on both CT and MRI. MRI appeared to be essential
for tumor detection. For tumor delineation itself, the CI of
the GTV was significantly higher on MRI and ranges on
CT were wider. However, median differences were small
(0.05) and may not be considered clinically relevant. For
the CTV, no significant difference was found, since inter-
observer differences are blurred when expanding structures
while uniformly excluding the skin and chest wall. How-
ever, more tumor spiculations and irregularities were ob-
served on MRI due to its high spatial resolution (Table 1,
Figure 2 Small peripheral branches in the transversal plane. (a) CE-MRI and (b) CE-CT.
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GTV conformity on MRI compared to CT.
The more irregular and spiculated tumor visualization on
CE-MRI might have caused the significantly larger target
volumes on MRI. Thin branches in the cranio-caudal orFigure 3 3D GTV delineations of 4 different observers in the transver
(b) Preoperative CE-CT (c) Clinical postoperative CT.medio-lateral direction caused a relatively large volume ex-
pansion when applying a CTV margin. Even though large
volumes can lead to increased toxicity and worse cosmesis,
these effects do not outweigh the chances of not including
peripheral tumor branches in the target volume, especiallysal and sagittal plane in one patient on. (a) Preoperative CE-MRI
Table 2 Parameters of interobserver variability (misdelineations excluded from analysis)
CT MRI
Median Range Median Range p-value
Mean volume (cm3)
GTV 2.1 0.3 – 21.3 2.7 0.4 – 19.4 <0.001
CTV 48.1 27.7 – 137.3 59.0 30.4 – 153.1 <0.001
Conformity index
GTV 0.56 0.11 – 0.83 0.61 0.37 – 0.78 <0.001
CTV 0.82 0.39 – 0.93 0.84 0.47 – 0.93 0.123
Mean dCOM (mm)
GTV 1.1 0.3 – 12.8 1.2 0.3 – 3.6 0.245
CTV 1.4 0.3 – 13.6 1.8 0.1 – 4.8 0.836
CI Conformity Index, GTV gross tumor volume, CTV clinical target volume, dCOM center of mass distance.
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among observers, we acknowledge that no definitive state-
ments can be made about the accuracy of the delineations,
with the lack of pathologic validation of these branches as
the gold standard. A pathology study must validate whether
these branches are actual tumoral extensions or rather fi-
brotic strands or interstitial reactions, before standard in-
clusion of these branches in the preoperative GTV. With
the implementation of high resolution imaging, the strict
boundary between the GTV and the CTV with its micro-
scopic spread might be fading. The appropriate preopera-
tive CTV margin on MRI is therefore subject to debate and
will also be further refined according to the future informa-
tion about the appearance of local recurrences in the breast
in the APBI studies [22].
In the last decade, several other attempts have been made
to improve the current postoperative target volume delinea-
tion (Table 3b and c). Delineation on postoperative MRI re-
sulted in contradicting results [8,9]. Jolicoeur et al. found
an improved IOV and smaller volumes, while Giezen et al.
found similar volumes with a degraded IOV. In two other
studies, IOV was assessed on postoperative CT while pre-
operative CE-CT images in the same treatment position
were provided [11,12]. This resulted in an improved IOV in
one of these studies. Preoperative delineation was studied
on CE-CT by Boersma et al., resulting in a low IOV, which
was in line with our study findings (Table 3d) [11].
Our reported findings on preoperative MRI-guided
delineation resulted in high and stable conformity among
observers (Table 3e). Furthermore, our preoperatively de-
lineated GTVs were considerably smaller compared to
postoperative volumes reported in literature (Table 3a).
CTVs were larger, although preoperative volumes would
have less outliers since there is no seroma formation. The
larger CTVs in our study were caused by a uniform
1.5 cm volume expansion, while the postoperative results
in Table 3a reflect ‘boost’ volumes, in which the micro-
scopic resection margin is often subtracted from thismargin. PTVs were not compared in this study, since PTV
margins are institution-dependent due to the method of
position verification being practiced. These PTV margins
might even be changed or improved in a preoperative set-
ting, due to less volume distortions. Overall, the high CI in
combination with the small and stable volumes in this
study, imply that a future neoadjuvant irradiation would
be more accurate and lead to less toxicity.
When comparing our results to published data in
Table 3, we have to be aware of the different methods used
in the other studies. For instance, the method of CI calcu-
lation, observer backgrounds and multi-centricity of a
study can influence the observed results regarding IOV
[29]. Interobserver studies often use small patient groups
due to the high workload (Table 3). Furthermore, it has to
be noted that the CI is volume dependent. The smaller the
volume being studied, the more the CI is influenced by
small interobserver differences. This especially accounts
for our small preoperative GTVs, but also emphasizes that
when comparing different studies, the studied volume (i.e.
GTV, TB, CTV or PTV) must be taken into account.
Can we, from the results of this study, conclude that MRI
superior to CT for preoperative tumor delineation? In this
study, MRI was essential for tumor detection. However, al-
ternatives for tumor detection can be considered, e.g. opti-
mizing CT parameters like contrast-enhancement of the
tumor, or clearly marking the tumor by fiducials. This
might be easier to implement, less time consuming and less
expensive. When using preoperative imaging for a pre-
operative irradiation or ablative interventional technique,
treating another area but the GTV would be unacceptable.
Furthermore, more detail could be visualized by MRI,
which could contribute to an accurate target definition.
Therefore, in our future studies, CE-MRI in radiotherapy
supine position will be used in addition to CT, as CT is re-
quired for treatment planning. In our institute, an MRI lin-
ear accelerator is being developed in collaboration with
Philips Medical Systems (Best, The Netherlands) and Elekta










a) CT Struikmans 2005 [4] 18 5 TB Mean 20 (6.4-75.8) CIpairs Mean 0.56 (0.39-0.74)
Petersen 2007 [5] 30 3 TB Mean 48.7 (10.3-189.3) CIcommon Mean 0.61 (0.27-0.84)
dCOM 0.5-1.1* (SD 0. 5–1.8)
Hurkmans 2009 [6] 10 4 TB 40 CIcommon Mean 0.31
(range 0.11 – 0.52)
Coles 2009 [7] 12 2 TB 29.0 (SD 28.5) dCOM Median 3 (range 1–9)
18.7 (8–116)
Jolicoeur 2011 [8] 66 3 TB 13.7 CIcommon Mean 0.66
Giezen 2012 [9] 15 4 TB 27 (SD 25) CIgen 0.52 (SD 0.21)
dCOM 4 (SD 3)
Van Mourik 2010 [10] 8 13 CTV n.a. CIpairs 0.61
# (range 0.35 – 0.79)
dCOM 7.25 (2.73 – 26.87)
Boersma 2012 [11] 26 5 CTV 41.9 (SD 34) CIpairs 0.36 (SD 0.21)
dCOM 11 (SD 8)
Van den Assem 2012 [12] 19 3 CTV 37.6 CIpairs Mean 0.59
dCOM Mean 5.5
Landis 2007 [13] 29 4 PTV 202 (65–492) CIpairs 0.76 (0.52-0.92)
dCOM 2.5 (0. 7–11.5)
b) MRI Jolicoeur 2011 [8] 66 3 TB 10.1 CIcommon Mean 0.96





Boersma 2012 [11] 26 5 CTV 36 (SD 31) CIpairs 0.36 (SD 0.19)
dCOM 10 (SD 7)
Van den Assem 2012 [12] 19 3 CTV 34.7 CIpairs Mean 0.68
dCOM Mean 2.9
d) Preop CT Boersma 2012 [11] +
vd Leij 2012 [18]
(same dataset)
26 5 GTV 0.99 CIpairs 0.45 (SD 0.22)
dCOM 4.3 (SD 7.6)




12 4 GTV 2.1 CIpairs 0.56 (0.11 – 0.83)
dCOM 1.1 (0.3 – 12.8)
CTV 48.1 CIpairs 0.82 (0.39 – 0.93)
1.4 (0.3 – 13.6)
e) Preop MRI This study
(excluding 2 misdelineations)
12 4 GTV 2.7 CIpairs 0.61 0.37 – 0.78)
dCOM 1.2 (0.3 – 3.6)
CTV 59.0 CIpairs 0.84 (0.47 – 0.93)
dCOM 1.8 (0.1 – 4.8)
*Range of the mean dCOM in x-y and z-direction and range in SD.
#CI values of one observer with all twelve observers were averaged.
¶Volume, CI and dCOM: reflected in median (range) or mean ± SD, unless stated differently.
TB Tumor Bed volume, GTV Gross Tumor Volume, CTV Clinical Target Volume, PTV Planning Target Volume.
CI Conformity Index, method of analysis (common, pairs, general) as described by Van Kouwenhoven et al. [27].
dCOM Distance between the Centers of Mass (mm).
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tumor tracking using MRI during radiotherapy, which
makes it possible to adapt the plan to the actual tumor pos-
ition. The results of our study show that a preoperative
irradiation of breast tumors could be beneficial in terms
of delineation consistency and treatment volumes. There
would be more certainty that the correct target is delin-
eated when the tumor is in situ. Moreover, preoperative tar-
get volumes would probably be more stable in the absence
of seroma formation, and not being subject to seroma
shrinkage [17,31]. The advantages of preoperative CE-MRI
for treatment planning will be further studied with respect
to the dosimetric consequences [32]. CE-MRI in supine
position could also be used for other purposes. For in-
stance, it might provide additional information to improve
the consistency in target volume definition in standard
postoperative CT-guided delineation [11]. Furthermore, it
might aid tumor localization for breast conserving surgery
or interventional procedures [33].
Conclusions
In conclusion, preoperative target volume delineation re-
sulted in small treatment volumes with a high consistency
among observers. MRI appeared to be necessary for tumor
detection and the visualization of irregularities and spicula-
tions. Regarding delineation of the tumor itself, no clinically
relevant differences in interobserver variability among im-
aging modalities were observed. These results will be used
to study the potential for a future MRI-guided and neoadju-
vant radiotherapy.
Additional file
Additional file 1: Parameters of interobserver variability including
misdelineations on CT, which resulted in CIs of 0.00 and high
dCOMs. In the manuscript, these outliers were excluded from analysis
and shown in Table 2.
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